Navigation Links
Imago BioSciences Announces Preclinical Data on LSD1 Inhibitor at Annual Meeting of the American Society of Hematology (ASH)
Date:12/7/2015

SAN FRANCISCO, Dec. 7, 2015 /PRNewswire/ -- Imago BioSciences, Inc., a biotech company developing innovative therapeutics for myeloid diseases, today announced a presentation at the 57th ASH Annual Meeting this week in Orlando, Florida.  The oral presentation titled "Lysine-Specific Histone Demethylase, LSDI (KDM1A) As a Novel Therapeutic Target in Myeloproliferative Neoplasms," outlines the beneficial effects including a reduction in mutant cells and reversal of fibrosis by inhibiting LSD1 in a well-established mouse model of myelofibrosis.

"We are delighted to be a part of the team generating these important data.  These are the first data to implicate LSD1 in the pathogenesis of a myeloproliferative neoplasm disease such as myelofibrosis," said Hugh Young Rienhoff, Jr. M.D., CEO at Imago BioSciences and a co-author of the study. "We are enthusiastic about the potential clinical benefit myelofibrosis patients might enjoy given the unmet need for a medicine that alters the natural history of this vicious disease.  The biology underlying these experiments directly advances our ongoing research and development of LSD1 inhibitors for the treatment of myeloid diseases."

Recent studies have shown that the lysine-specific demethylase LSD1, participates in the balance between hematopoietic cell proliferation and differentiation in hematopoietic stem and progenitor cells.  LSD1 appears essential for maintaining malignant myeloid stem and progenitor cells in the undifferentiated and self-renewing state.   

In the experiment presented, mice with myelofibrosis secondary to the activated thrombopoietin receptor (MplW515L) were treated with an oral Imago LSD1 inhibitor.  Treated mice showed reduced splenomegaly, decreased platelet counts, a marked reduction in key cytokines, a resolution of bone marrow fibrosis and a reduction of mutant allele burden over the course of the 4 week treatment period.  These and other unpublished data support LSD1 as a valid drug target in myelofibrosis.  The Imago LSD1 inhibitor will enter the clinic next year.

About Imago BioSciences

Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians.  The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases.  Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.  More information is available at www.imagobio.com.

Investor and Media Contact:
info@imagobio.com
415-529-5055

 


'/>"/>
SOURCE Imago BioSciences
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. New Hudsonville-Based Biomedical Startup, Imago Prints, Uses Patient-Specific Ultrasound Data to Produce One-of-a-Kind 3D Printed Renderings of Infants During Pregnancy
2. Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals
3. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
4. Northstar Biosciences Launches All Natural Skincare Solutions
5. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
6. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
7. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
8. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
9. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
10. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
11. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/14/2019)... (PRWEB) , ... March 14, 2019 , ... The growth ... challenges for companies to keep up. Traditional Regulatory intelligence (RI) ... adapting technology to get global Regulatory teams right Insights faster and cheaper. With a ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... for preclinical research organizations. It is a low code, GDPR/21 CFR Part ... facilities, innovative technology-driven automated data capture and seamless data and information management. ...
(Date:3/9/2019)... (PRWEB) , ... March 07, 2019 , ... ... is a pioneer in the development and commercialization of high performance, cutting-edge cell ... a leading European CRO with GLP-certified expertise in cardiovascular pharmacology and electrophysiology, are ...
(Date:2/27/2019)... ... 27, 2019 , ... Lajollacooks4u is pleased to announce that ... and cooking events company will be offering a new cooking package available to ... team-building event involves pairing two popular items together – tacos and tequila – ...
Breaking Biology Technology:
(Date:3/18/2019)... ... March 18, 2019 , ... 3Bar ... microbial solutions announce today they have entered into an agreement for 3Bar to ... for biologic nitrogen fixation for corn. This agreement ensures an easy-to-use solution for ...
(Date:3/13/2019)... ... 2019 , ... Sleep problems constitute a global epidemic that threatens health and ... One billion people worldwide suffer from sleep apnea - a condition that ... of whom go undiagnosed. Today, Beddr , the sleep health technology startup, announced ...
(Date:3/9/2019)... ... March 07, 2019 , ... Murrieta Genomics , ... full day workshop presented by University of California Riverside’s EPIC SBDC focused on ... a.m. to 6 p.m. on Tuesday, March 17, 2019. The location is the Highlander ...
Breaking Biology News(10 mins):